Denis Cominetti

Denis Cominetti

Auto-generated profile, based on publicly available information

Denis Cominetti

Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2013 in Biochemical Pharmacology
Verified
Journal Article
Closed access
GCGiuliana Cassinelli
Giuliana Cassinelli
Cinzia LanziCinzia Lanzi
Cinzia Lanzi
MTM. Tortoreto
M. Tortoreto
DCD. Cominetti
D. Cominetti
GPGiovanna Petrangolini
Giovanna Petrangolini
FZF. Zunino
F. Zunino

15 September 2013 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
MTM. Tortoreto
M. Tortoreto
FBFabio Bozzi
Fabio Bozzi
ETE. Tamborini
E. Tamborini
CMC. Morosi
C. Morosi
PCP.G. Casali
P.G. Casali
Purpose: To explore the value of triazines in solitary fibrous tumor (SFT). Experimental Design: We retrospectively reviewed 8 cases of patients with SFT treated with dacarbazine (1,200 mg/m2 every 3 weeks) as from January 2012. Then, we studied a dedifferentiated-SFT subcutaneously xenotransplanted into severe combined immunodeficient (SCID) mice. Dacarbazine, temozolomide, sunitinib, bevacizumab, and pazopanib were administered at their reported optimal doses for the mouse model when mean tumor volume (TV) was about 80 mm3; each experimental groups included 6 mice. Drug activity was assessed as tumor volume inhibition percentage (TVI%). Dacarbazine was tested according to two different schedules of administration. One hunded twenty days after treatment interruption, mouse tumor samples were analyzed. Results: Among the eight patients treated with dacarbazine, best response evaluation criteria in solid tumors responses (RECIST) were three partial responses, 4 stable disease, 1 progression. Two responsive patients had paraneoplastic hypoglycemia that disappeared after 10 days from starting dacarbazine. In the dedifferentiated-SFT xenograft model, dacarbazine and temozolomide showed the highest antitumor activity (about 95% TVI), confirmed pathologically. Sunitinib and pazopanib were only marginally active (52% and 41% TVI, respectively), whereas bevacizumab caused a 78% TVI. No tumor regrowth was observed up to 100 days from end of treatment with temozolomide and dacarbazine, whereas secondary progression followed sunitinib, pazopanib, and bevacizumab interruption. Conclusions: Dacarbazine as single agent has antitumor activity in SFT. Our preclinical results suggest a cytotoxic effect of temozolomide and dacarbazine, as compared with a cytostatic role for sunitinib, pazopanib, and bevacizumab. A phase II study on dacarbazine in advanced SFT is planned. Clin Cancer Res; 19(18); 5192–201. ©2013 AACR.

1 November 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
MTM. Tortoreto
M. Tortoreto
GBG.G. Baldi
G.G. Baldi
GGGiovanni Grignani
Giovanni Grignani
ATAngela Toss
Angela Toss
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni

26 July 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VSVirginia Spanò
Virginia Spanò
MPMarzia Pennati
Marzia Pennati
BPBarbara Parrino
Barbara Parrino
ACAnna Carbone
Anna Carbone
AMAlessandra Montalbano
Alessandra Montalbano
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni

18 April 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MCMichelandrea De Cesare
Michelandrea De Cesare
DCDenis Cominetti
Denis Cominetti
VDValentina Doldi
Valentina Doldi
ALAlessia Lopergolo
Alessia Lopergolo
MDMarcello Deraco
Marcello Deraco
Nadia ZaffaroniNadia Zaffaroni
Nadia Zaffaroni
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin